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Purpose: Currently available agents for the treatment of advanced
stage non-small cell lung cancer (NSCLC) have limited efficacy. S-1
is a novel formulation of oral fluoropyrimidine shown to be tolerable
and active in patients with NSCLC in Japan. We conducted a
multicenter phase II study in previously treated patients with
NSCLC to evaluate the efficacy of single-agent S-1 in a predomi-
nantly non-Asian population.
Patients and Methods: Patients with advanced NSCLC and previ-
ously treated with only one line of chemotherapy received oral S-1
at 30 mg/m2 every 12 hours for 14 consecutive days followed by a
7-day rest until meeting discontinuation criteria. The primary end
point was to evaluate the overall response rate.
Results: Fifty-seven patients were accrued from 21 centers across
the United States. Overall response rates and stable disease accord-
ing to independent review were 7.1% and 48.2%, respectively, with
a disease control rate of 55.3%. Progression-free survival was 2.9
months, median overall survival 7.3 months, and 1-year survival
31.6%. There were no significant differences in survival according
to histologic subtype. The treatment was well tolerated, with the
most common treatment-related side effects being nausea (54%) and
diarrhea (49%).
Conclusion: Single-agent S-1 is well tolerated and has activity
comparable with the other agents approved for use in recurrent/
relapsed NSCLC.
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(J Thorac Oncol. 2011;6: 790–795)
Lung cancer is the most common cause of cancer-relateddeath in the United States, with 159,390 deaths estimated
by the American Cancer Society for the year 2009.1 Non-
small cell lung cancer (NSCLC) accounts for approximately
87% of lung cancer cases,2 with at least two thirds of patients
presenting with locally advanced or advanced disease at
diagnosis.3 Even among patients with early-stage disease,
distant relapses are common despite the use optimal surgery
and adjuvant chemotherapy.4
Although first-line chemotherapy is associated with
improved survival and quality of life in patients with ad-
vanced NSCLC, virtually all patients eventually develop
progressive disease (PD) requiring additional treatment.
There are currently three agents (docetaxel, pemetrexed, and
erlotinib) approved for the use in patients with metastatic
NSCLC progressing after a platinum-based doublet therapy
in the United States. In other countries such as Japan, ge-
fitinib and tegafur/uracil have also been approved. The out-
comes for second-line therapy remain suboptimal, with over-
all response rates (ORRs) in this setting of less than 10%,
progression-free survival (PFS) less than 3 months, median
overall survival (OS) between 5.7 and 8.3 months, and 1-year
OS between 30% and 37%.5–8 Therefore, there is a great need
for the development of new agents or combination regimens
in this patient population.
Since the first description by Heidelberger et al.9 in
1957, 5-fluorouracil (5-FU) has been successfully used in a
variety of solid tumors, particularly colorectal cancer, and
upper gastrointestinal malignancies. In patients with ad-
vanced NSCLC, however, 5-FU has demonstrated minimal
activity.10 One of the possible explanations for this lack of
benefit from 5-FU might be the presence of higher dihydro-
pyrimidine dehydrogenase (DPD) activity in NSCLC com-
pared with other solid tumors.11,12 On entering the cell, 5-FU
may be metabolized into the anabolic or catabolic pathways,
with the former represented by phosphorylation into active
metabolites and the latter through the action of DPD into
inactive metabolites.13 The rapid degradation of approxi-
mately 90% of administered 5-FU by DPD significantly
limits its activity, with decreased amounts of the drug avail-
able for the anabolic pathway. Oral 5-FU is associated with
erratic absorption, mainly due to the high DPD activity in the
liver and gastrointestinal walls. One attractive option to
circumvent this rapid DPD metabolism, while avoiding the
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inconvenient use of costly implantable access devices and
portable infusion pumps, has been the use of oral fluoropy-
rimidine prodrugs in combination with DPD inhibitors. Oral
fluoropyrimidines may be broadly divided into 5-FU prod-
rugs, 5-FU combined with a DPD inhibitor, and 5-FU prod-
rugs combined with a DPD inhibitor. The 5-FU prodrugs,
such as capecitabine and tegafur, were designed to undergo
intact absorption through the gastrointestinal tract with pos-
terior enzymatic activation to 5-FU in the liver or within the
tumor. The most commonly used irreversible DPD inhibitor
is eniluracil, whereas reversible inhibitors include uracil and
5-chloro-2,4-dihydropyrimidine.14 Orotate phosphoribosyl-
transferase (OPRT) is the enzyme that activates 5-FU in the
gastrointestinal tract.15 As gastrointestinal toxicity is common
in patients treated with fluoropyrimidines and OPRT is not
present in the tumor, inhibition of this enzyme may decrease
toxicity without affecting the antitumor efficacy. S-1 is the
combination of the prodrug tegafur, the reversible DPD
inhibitor 5-chloro-2,4-dihydropyrimidine, and the OPRT in-
hibitor oxo. S-1 is currently marketed in Japan for the
treatment of head and neck cancer, colorectal cancer, breast
cancer, pancreatic cancer, biliary cancer, gastric cancer, and
NSCLC.
The recommended doses for single-agent S-1 based on
phase I studies conducted in western countries were 50
mg/m2 daily for 21 days every 4 weeks,16 40 to 50 mg/m2
daily for 28 days every 5 weeks,17,18 or 30 mg/m2 twice daily
for 28 days every 5 weeks.19 An alternative approach, used in
Japanese studies, was to administer the dose according to the
body surface area, where patients with body surface area less
than 1.25 m2, 1.25 to 1.5 m2, and more than 1.5 m2 receiving
40 mg twice daily, 50 mg twice daily, or 60 mg twice daily,
respectively, for 28 consecutive days.20 The toxicity profile
from these phase I trials differed significantly based on the
geographic region of study, with predominant hematological
toxicities observed in Japanese studies19 and gastrointestinal
toxicities in studies from North America or Europe.16,17,19
We performed a phase II study to evaluate the efficacy
of single-agent S-1 in a predominantly non-Asian population
of pretreated patients.
PATIENTS AND METHODS
Study Population
Patients with histologically and/or cytologically proven
NSCLC who have had PD after a platinum-based doublet
therapy, Eastern Cooperative Oncology Group performance
status 0 or 1, and adequate organ functions were eligible to
participate in the study.
Patients were excluded if they had mixed small cell and
non-small cell histology, received investigational therapy
within the past 30 days, systemic therapy for NSCLC within
the previous 3 weeks, radiation therapy to a target lesion
within the previous 3 months unless there was disease pro-
gression in that lesion and there were additional target le-
sions, radiation therapy within the last 2 weeks, and serious
medical conditions including other malignancies, symptom-
atic brain metastases not controlled by corticosteroids, lepto-
meningeal metastases, psychiatric disorder, known human
immunodeficiency virus or acquired immunodeficiency syn-
drome-related illness, myocardial infarction within the last 6
months, severe or unstable angina, and congestive heart
failure with New York Heart Association class III or IV.
The following medications were prohibited during the
study due to their potential interaction with S-1: sorivudine,
uracil, cimetidine, folinic acid, flucytosine and dipyridamole
due to enhanced S-1 activity, allopurinol, which may de-
crease S-1 activity, and phenytoin, which may have its
activity enhanced by S-1.
The protocol, protocol amendments, informed con-
sent, and other documents pertaining to the study were
approved by the institutional review board of each partic-
ipating center. This trial is registered on the clinical trials
site of the US National Cancer Institute web site (trial
registration NCT00227552).21
Treatment Plan
S-1 was supplied by Taiho Pharma USA, Inc. (NJ) and
was administered orally, under fasting condition (defined as 1
hour prior or 1 hour after a meal) at 30 mg/m2 every 12 hours
for 14 days followed by a 7-day rest, with each cycle of
therapy lasting 21 days. S-1 was supplied as 15-mg or 20-mg
capsules. Treatment was continued until evidence of disease
progression, development of intolerable side effects, or with-
drawal of consent.
In case of grade 3 drug-related adverse events (AEs),
the treatment was interrupted and restarted at a lower dose
after improvement to baseline or grade 1. Patients who
developed renal failure during therapy required an estimated
creatinine clearance of at least 30 ml/min to restart S-1.
Patients requiring more than a 3-week recovery period from
the scheduled starting date of the next cycle were removed
from the study. The two dose reductions allowed for S-1 were
25 mg/m2 (first dose reduction) and 20 mg/m2 (second dose
reduction).
Study Assessments
Tumor response was evaluated by the RECIST criteria.
Imaging studies with CT scans were performed within 21
days before day 1 and repeated at the end of every even cycle
until disease progression. Nevertheless, if a patient re-
sponded, response confirmation was to be obtained through
tumor assessments at least 4 weeks after the first documen-
tation of response. Patients then returned to their original
even-cycle schedule of assessments. AEs were graded ac-
cording to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events version 3.0. Physical exam-
ination and laboratory chemistry were performed at baseline
and on day 1 of each cycle, whereas hematology was per-
formed also on days 8 and 15.
Statistical Analysis
This was an open-labeled, multicenter, single-arm,
phase II study divided into three stages including futility
stage (stage 1), decision stage (stage 2), and precision im-
provement stage (stage 3). The primary end point of the study
was to evaluate the antitumor activity of S-1, assessed by
ORR including complete response (CR) and partial response
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(PR). The secondary objectives included duration of response
and PFS, OS, and safety profile. Based on the exact binomial
probability distribution Simon two-stage Minimax design
with acceptable ORR (p1) of 20%, unacceptable ORR (p0) of
8%, type I error () of 0.05, and type II error () of 0.2, the
initial sample size was 50 patients. The patient sample for the
first stage was 30, and the study would go to the second phase
only if 10% or more patients achieved a confirmed response.
For the study to be considered sufficiently efficacious to
warrant further evaluation, the criteria to proceed to the third
stage was an ORR in 16% or more patients. The sample for
stage 3 would be estimated based on the ORR for the first
two stages to achieve a lower 95% one-sided confidence
bound of 10% or more, ranging from 35 additional patients in
case of ORR of 16% to no additional patients in case of ORR
of 20%. Assuming a 10% rate for loss to follow-up or
nonevaluability for ORR assessment, the projected accrual
for all stages combined was between 55 and 95 patients.
The primary statistical assessment of ORR at the end of
the study was based on the Independent Reader assessment of
the images, whereas the decision to proceed to stages 2 and 3
were based on ORR assessment by the on-site Investigators.
RESULTS
Patient Demographics
A total of 57 patients from 21 US centers were enrolled
into the study. Demographics and baseline characteristics are
described in Table 1. Median age was 62 years (range:
44–85). Most patients were men (61%), whites (88%), and
former smokers (72%). Adenocarcinoma was the most com-
mon histology (46%) followed by squamous cell carcinoma
(32%). Four patients (7%) received prior systemic therapy in
addition to the first-line therapy including one patient treated
with second-line erlotinib and three patients who had re-
ceived adjuvant chemotherapy. Prior radiotherapy was ad-
ministered in 58% of the patients.
Efficacy
The best ORR by Investigator and Independent Reader
assessments were 8.8% (95% confidence interval [CI]: 2.9–
19.3%) and 7.1% (95% CI: 2.0–17.3%), respectively. Ac-
cording to the Independent Reader, 27 (48.2%) patients had
stable disease (SD), 19 (33.9%) had PD, and six (10.7%)
were considered not evaluable (Table 2). Among the respond-
ing patients, the median duration of response was 6 months
(95% CI: 3.8–18.8 months).
The PFS was 2.9 months (95% CI: 1.7–4.1 months),
with 15.5% (95% CI: 6.5–28.1%) of patients without pro-
gression at 6 months (Figure 1). The median OS for all
patients was 7.3 months (95% CI: 6.0–9.7 months) with
survival rates at 6, 12, and 18 months of 59.6%, 31.6%, and
17.5%, respectively (Figure 2). PR and SD were 0% and
44.4%, respectively, for squamous cell carcinoma, and 10.5%
and 50%, respectively, for nonsquamous histology. Median
OS for patients with squamous and nonsquamous histologies
were 7.0 months (95% CI: 3.4–9.3) and 9.1 months (95% CI:
5.7–10.3), respectively. The demographics of patients achiev-
ing PR or PFS 6 months are described in Table 3.
TABLE 2. Response Rate by Independent Assessment (n  56)
Total
(n  56)
Squamous
Cell
(n  18)
Nonsquamous
Cell
(n  38)
Response
Complete response 0 (0%) 0 (0%) 0 (0%)
Partial response 4 (7.1%) 0 (0%) 4 (10.5%)
Stable disease 27 (48.2%) 8 (44.4%) 19 (50%)
Progressive disease 19 (33.9%) 7 (38.9%) 12 (31.6%)
Not available 6 (10.7%) 3 (16.7%) 3 (7.9%)
Overall response rate, n (%) 4 (7.1%) 0% 10.5%
Disease control rate, n (%) 31 (55.3%) 44.4% 60.5%
TABLE 1. Patient Characteristics at Baseline
Characteristics n Percentage
Age
Mean 62
Range 44–85
Sex
Male 35 61
Female 22 39
Ethnicity
White 50 88
Smoking status
Current smoker 12 21
Former smoker 41 72
Never smoker 4 7
Histology
Adenocarcinoma 26 46
Squamous cell 18 32
Large cell 7 12
Other 6 10
ECOG performance status
0 13 23
1 44 77
Disease stage
IIIB 1 3
IIIB with pleural effusion 2 2
IV 54 95
Previous radiotherapy
Yes 33 58
No 24 42
Previous systemic therapy
Yes 4 7
No 53 93
Best response to previous treatment
CR 4 7
PR 8 14
SD 22 39
PD 15 26
Unknown 8 14
CR, complete response; PD, progressive disease; PR, partial response; SD, stable
disease; ECOG, Eastern Cooperative Oncology Group.
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Safety
All 57 patients received at least one dose of S-1 and
were included in the safety analysis. The total number of
cycles administered was 257, with a median number of three
cycles (range: 1–38). Cycle 4 was initiated in 46% of patients
and cycle 8 in 25% of patients. Seven percent of patients
received more than 10 cycles.
The most common treatment-related AEs were nausea
(54%), diarrhea (49%), fatigue (40%), vomiting (39%), and
anorexia (32%) (Table 4). Anemia occurred in 10 patients
(17%) and was the most common hematologic AE, followed
by thrombocytopenia (5%), and neutropenia (3%). There
were no cases of neutropenic fever. Treatment-related grade
3 toxicities occurred in 24 patients (42%) and grade 4 in three
patients (5%). Diarrhea occurred in 12 patients (21%) and
represented the most frequent grade 3/4 toxicity. Other com-
mon grade 3/4 AEs included fatigue (12%), dehydration
(9%), and anorexia (7%).
Eight patients (14%) died during the treatment, includ-
ing one death due to acute myocardial infarction considered
possibly related to the study medication, one death due to
unknown cause, and six patients with tumor progression.
DISCUSSION
The Japanese Lung Cancer Working Group22 reported
the first phase II study on single-agent S-1 in previously
FIGURE 1. Progression-free survival.
FIGURE 2. Overall survival.
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untreated patients with advanced stage NSCLC administered
according to the previously described earlier phase I20 for 28
consecutive days every 6 weeks. Among the 59 assessable
patients, 13 achieved PR (22%), including 10 of 38 patients
with adenocarcinoma (26.3%) and 2 of 20 patients with
squamous cell carcinoma (10%). The median and 1-year OS
were 10.2 months and 41%, respectively. Both gastrointesti-
nal and hematological toxicities were mild and did not require
dose interruption.
Several studies showed the feasibility of first-line S-1
combinations in patients with advanced NSCLC, with good
efficacy and tolerability. The combination of S-1 and cisplatin
showed acceptable toxicity and was associated with response
rates of 47%, median OS of 11 months, and 1-year OS of 45%
in 55 evaluable patients.23 The combination of S-1 and carbo-
platin was well tolerated and resulted in response rate, PFS, and
OS in 29 evaluable patients of 31%, 4.5 months, and 16 months,
respectively.24 The West Japan Thoracic Oncology Group
350525 showed response rate of 28.6%, disease control rate of
71.4%, median PFS of 4.9 months, and median OS of 15 months
in patients with advanced NSCLC treated with S-1 and irinote-
can. The response rate, PFS, and OS for the combination of S-1
and docetaxel in 60 patients with previously untreated advanced
NSCLCwere 30%, 4.9 months, and 15.2 months, respectively.26
In pretreated patients with NSCLC, a phase II study
evaluated S-1 at the dose of 80 mg/m2 twice daily for 28 days
every 6 weeks.27 Among the 27 enrolled patients, five
achieved PR (19%). Median PFS and OS were 3.4 months
and 10.2 months, respectively. The treatment was overall
well tolerated, with less than 10% grade 3 or 4 toxicities.
Although both response rate and survival were lower in our
study compared with the Japanese phase II trial in pretreated
patients, the median OS at 12 and 18 months (31.6% and
17.5%) was encouraging. These differences are not surpris-
ing, as it is now well known that Asians with advanced
NSCLC have better outcomes than whites with NSCLC. The
treatment schedule in the United States was established based
on a phase I study, which demonstrated that S-1 dosed at 30
mg/m2 twice daily for 14 days with a 7-day recovery period
was safe and well tolerated.28 This dosage of S-1 was re-
peated every 3 weeks, which is the standard treatment sched-
ule for NSCLC. Furthermore, similar to the large phase III
trial on S-1 plus carboplatin,29 there were no large differences
in outcomes according to histological subtype. Therefore,
unlike pemetrexed,30 which has selective activity in patients
with nonsquamous histology, S-1 does not seem to have
differential activity based on histology.
S-1 was well tolerated especially for hematological
toxicities compared with other agents, although diarrhea was
higher in this study. It is, therefore, important to provide
patients with loperamide and instruct the patient on how to
use it at the first sign of diarrhea. The primary dose-limiting
toxicity in the US/European clinical trials was diarrhea,
whereas hematological toxicities were observed in the Japa-
nese studies. Differences in toxicity, particularly gastrointes-
tinal toxicity, of 5-FU in patients of different regions have
been described in the literature,31 although the reasons for
regional differences in toxicity caused by fluoropyrimidines
are not completely defined.
In summary, S-1 is a convenient oral medication for
patients with previously treated advanced stage NSCLC, with
similar response rates, when compared with the available
second-line therapies, acceptable toxicity, and clinical benefit
in all histological subtypes. Although S-1 was well tolerated
and achieved efficacy similar to other agents tested in this
setting, this study failed to meet its objectives. Lower tissue
TABLE 3. Demographics of Patients Achieving Partial Response or Progression-Free Survival 6 mo
Age (yr) Sex ECOG PS Smoking Status Histology Best ORR PFS (mo) OS (mo)
52 Male 0 Former Adenocarcinoma PR 23.9 26.9
58 Female 0 Former Other SD 23.2 29.1
47 Male 1 Current Adenocarcinoma PR 10.5 26.9
55 Female 1 Former Large cell SD 7.1 10.4
58 Female 0 Current Other SD 6.5 27
74 Male 0 Former Squamous SD 6.1 16.3
70 Male 1 Former Other PR 5.7 7.3
62 Male 1 Current Large cell PR 5.1 7.4
ORR, overall response rate; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PFS, progression-free survival; OS, overall survival.
TABLE 4. Treatment-Related Adverse Events Reported in At
Least 10% of Patients
Adverse Events
Any Grade Grade >3
No. Percentage No. Percentage
Nonhematologic
Nausea 31 54 3 5
Diarrhea 28 49 12 21
Fatigue 23 40 7 12
Vomiting 22 39 1 2
Anorexia 18 32 4 7
Rash 13 23 1 2
Weight decrease 9 16 0 0
Stomatitis 9 16 2 3
Dysgeusia 8 14 0 0
Dehydration 7 12 5 9
Pruritus 6 10 0 0
Headaches 6 10 0 0
Hematologic
Anemia 10 17 1 2
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levels of thymidylate synthase were correlated with better
response to S-1 in patients with stomach and renal cell
cancer.32,33 It is possible that S-1 may be more active in such
a defined molecular subset of patients with NSCLC.
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